Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates(http://www.researchmoz.us/competitor-analysis-antibody-drug-conjugates-adc-report.html ) provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the way for a total of further 33 ADCs in clinical studies and further six ADCs in IND enabling studies. Adcetris posted US sales of US$ 138 mln in 2012 and with the start of marketing of Kadcyla.
About Us
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
Clinically useful, unconjugated monoclonal antibodies (mAbs) selectively recognize antigens that are preferentially expressed on or near tumor cells and exert their cytotoxic effects through mechanisms such as cell signaling, ADC Linker